September 24, 2026

Vaxxas Launches European Study to Explore Public Attitudes Toward Self-Administered Vaccine Delivery

February 26, 2026

Vaxxas in Global Consortium Awarded Tender by European Union to Develop Next-Generation Influenza Vaccines

January 8, 2026

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

December 15, 2025

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

November 11, 2025

Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Patch To Market

October 29, 2025

Vaxxas and ObvioHealth Sign New Agreement to Power Needle-Free Vaccination Technology Trials with ObvioGo®

August 25, 2025

Vaxxas secures ~A$90M in funding to commercialise needle-free vaccination delivery technology

March 19, 2025

Vaxxas Secures US Patent For Needle-Free Vaccination Manufacturing Technology

March 5, 2025

Newly Published Data Supports Effective Delivery of DNA-Based Vaccines Using Vaxxas’ HD-MAP

February 19, 2025

Vaxxas Completes Enrollment for Largest Clinical Trial of HD-MAP for Vaccine Delivery

February 6, 2025

Vaxxas Appoints Leading Global Vaccine Experts

January 23, 2025

Vaxxas and CEPI Advance Program for Needle-Free Thermostable mRNA Vaccines

January 14, 2025

Vaxxas Receives US BARDA Patch Forward Prize to Advance Microarray Patch for Vaccination

November 25, 2024

Vaxxas expands global IP portfolio for needle-free vaccination technology

November 15, 2024

Vaxxas CEO David Hoey recognised by AmCham for bilateral collaboration in biotechnology

October 29, 2024

Vaxxas licenses next-gen RSV vaccine candidate from the US National Institutes of Health

September 12, 2024

Vaxxas begins Phase I trial of needle-free avian flu vaccine

June 26, 2024

Research Australia and Vaxxas put Australian health innovation on the national agenda

May 22, 2024

Vaxxas ‘graduates’ from Queensland‐based Translational Research Institute

April 2, 2024

Vaxxas Leads Session on Alternative Vaccine Routes at World Vaccine Congress

January 23, 2024

Vaxxas recognised in inaugural Embassy of Australia Awards Gala

November 27, 2023

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary HD-MAP; Plan for Phase I/II Trial in The Gambia, Africa

October 19, 2023

Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)

August 23, 2023

Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch

July 25, 2023

Vaxxas Opening Statement to the Standing Committee on Industry, Science and Resources

June 19, 2023

Vaxxas Opens World-Class Manufacturing Facility To Produce Needle-Free Vaccine Patch

June 6, 2023

Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)

June 6, 2023

Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer

April 10, 2023

Brisbane’s new MedTech partnerships could change the world | The Australian

April 8, 2023

'A silver lining': how Covid ushered in a vaccines golden era | The Guardian

March 31, 2023

Ease-of-Use and Potential Self-Administration of Vaccination Shown with Vaxxas High Density Microarray Patch (HD-MAP)

February 23, 2023

Vaxxas CEO David Hoey joins Better Brisbane Alliance

February 16, 2023

Vaccines based on mRNA need to get out of the freezer

February 10, 2023

Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)

January 19, 2023

Vaxxas receives Australian Government grant to support Phase II clinical trials of needle-free COVID-19 vaccine

January 17, 2023

Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access

December 05, 2022

Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate

December 01, 2022

Vaxxas Appoints Doug Cubbin as Chief Financial Officer

November 8, 2022

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

September 20, 2022

Vaxxas receives $8.2 million grant to support manufacturing scale-up in its Australian manufacturing facility

July 27, 2022

Vaxxas patch worked for all Covid strains

May 31, 2022

Vaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration

May 17, 2022

Get a jab without the jab

May 12, 2022

Vaxxas receives REDI Fellowship Grant to support HD-MAP clinical trials

April 21, 2022

Vaxxas Welcomes Scott Fry Ph.D. as Chief Operating Officer

April 14, 2022

Vaxxas Welcomes Dan Devine as Chief Business Officer and General Counsel

March 31, 2022

Avalere Health Analysis - Microarray patches (MAP) could improve pandemic vaccination

March 23, 2022

Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches

June 02, 2021

Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas' Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine

October 05, 2020

Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

May 28, 2020

Vaxxas Announces That Merck Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate

May 28, 2020

Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate

May 28, 2020

Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial-scale Aseptic Processing Line for Vaccine Products Based on Vaxxas High Density Microarray Patch (HD-MAP)

March 17, 2020

Vaxxas Publication in PLoS Medicine Reveals Groundbreaking Clinical Research on Broad Potential of Novel High-Density Microarray Patch (HD-MAP) to Effeciently Deliver Vaccines Directly to the Skin, Enhancing Immunogenicity

March 17, 2020

Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study of Measles and Rubella Vaccination using Vaxxas' High Density Micro-Array Patch

February 09, 2015

Vaxxas Raises A$25 Million [US$20 Million] in Series B Venture Financing to Accelerate Commercialization of Novel Vaccine Platform

September 15, 2014

Vaxxas Initiates Research Project on Advancing Next Generation Technology for Polio Vaccine Delivery

August 26, 2014

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

October 09, 2012

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

October 09, 2012

Vaxxas Appoints David Hoey as Company's First CEO